Challenges and Advances in Gene Therapy Approaches for Neurodegenerative Disorders

Author(s): Aneesh Donde, Philip C. Wong, Liam L. Chen*

Journal Name: Current Gene Therapy

Volume 17 , Issue 3 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Introduction: The recent approval of Spinraza (nusinersen), an antisense oligonucleotide, by U.S. Food and Drug Administration to treat patients with spinal muscular atrophy, has reignited interests of researchers in designing and testing new gene therapy approaches to treat neurological disorders, in particular, to curb neurodegenerative diseases of the central nervous system which represent an ever-increasing public health burden to today's society.

Conclusion: This review highlights several key factors to be taken into consideration to design successful preclinical and clinical gene therapy experiments with respect to the vehicle of delivery and the route of administration to CNS-specific targets, with an additional focus on antisense oligonucleotide therapy and recent clinical trial developments.

Keywords: Gene therapy, Neurodegenerative disorder, Antisense oligonucleotide, Clinical trial, Viral vectors, Central nervous system.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 12 December, 2017
Page: [187 - 193]
Pages: 7
DOI: 10.2174/1566523217666171013124150
Price: $65

Article Metrics

PDF: 49